Global Pharmacovigilance Market Size, Status and Forecast 2019-2025
- Id : RNR-265034
- Category : Pharma Healthcare
- Publish Date : March-2019
- Publisher : Research-N-Reports
- Pages : 125
- Format : PDF
In 2018, the global Pharmacovigilance market size was million US$ and it is expected to reach million US$ by the end of 2025, with a CAGR of during 2019-2025. This report focuses on the global Pharmacovigilance status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Pharmacovigilance development in United States, Europe and China. The key players covered in this study - Eli Lilly and Company - ICON plc - Elsevier - Chiltern - Atlantic Research Group - Mapi Group - Accenture Plc. - Clinquest Group B.V. - GSK - PRA Health Sciences, Inc. Market segment by Type, the product can be split into - Chemotherapy - Contract Outsourcing Market segment by Application, split into - Pharma and Biotech Companies - Contract Research Organizations (CROs) - Business Process Outsourcing (BPO) Firms - Other Pharmacovigilance Service Providers Market segment by Regions/Countries, this report covers - United States - Europe - China - Japan - Southeast Asia - India - Central & South America The study objectives of this report are: - To analyze global Pharmacovigilance status, future forecast, growth opportunity, key market and key players. - To present the Pharmacovigilance development in United States, Europe and China. - To strategically profile the key players and comprehensively analyze their development plan and strategies. - To define, describe and forecast the market by product type, market and key regions. In this study, the years considered to estimate the market size of Pharmacovigilance are as follows: - History Year: 2014-2018 - Base Year: 2018 - Estimated Year: 2019 - Forecast Year 2019 to 2025 For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.